Citigroup Inc Adicet Bio, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 384 shares of ACET stock, worth $357. This represents 0.0% of its overall portfolio holdings.

Number of Shares

384

Previous 7,899 95.14%

Holding current value

$357

Previous $9,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.07 - $1.63 $8,041 - $12,249	-7,515 Reduced 95.14%	384 $0
Q2 2024 Aug 12, 2024	SELL	$1.21 - $2.4 $3,562 - $7,065	-2,944 Reduced 27.15%	7,899 $9,000
Q1 2024 May 10, 2024	BUY	$1.76 - $3.45 $9,444 - $18,512	5,366 Added 97.97%	10,843 $25,000
Q4 2023 Feb 09, 2024	BUY	$1.11 - $1.89 $5,203 - $8,860	4,688 Added 594.17%	5,477 $10,000
Q3 2023 Nov 09, 2023	SELL	$1.37 - $3.4 $35,015 - $86,900	-25,559 Reduced 97.01%	789 $1,000
Q2 2023 Aug 10, 2023	BUY	$2.13 - $7.13 $54,053 - $180,938	25,377 Added 2613.49%	26,348 $64,000
Q1 2023 May 11, 2023	SELL	$5.52 - $9.23 $436,460 - $729,806	-79,069 Reduced 98.79%	971 $5,000
Q4 2022 Feb 09, 2023	SELL	$7.72 - $21.27 $309,317 - $852,225	-40,067 Reduced 33.36%	80,040 $715,000
Q3 2022 Nov 10, 2022	BUY	$13.43 - $18.74 $1.57 Million - $2.19 Million	116,976 Added 3736.06%	120,107 $1.71 Million
Q2 2022 Aug 10, 2022	BUY	$10.26 - $20.81 $12,117 - $24,576	1,181 Added 60.56%	3,131 $46,000
Q1 2022 May 12, 2022	SELL	$11.53 - $19.97 $50,051 - $86,689	-4,341 Reduced 69.0%	1,950 $39,000
Q4 2021 Feb 10, 2022	BUY	$7.37 - $17.49 $15,093 - $35,819	2,048 Added 48.27%	6,291 $110,000
Q3 2021 Nov 10, 2021	BUY	$6.29 - $9.93 $26,688 - $42,132	4,243 New	4,243 $33,000

Others Institutions Holding ACET

# of Institutions

Shares Held

59.2M

Call Options Held

4.2K

Put Options Held

6.7K

View Full List

About Adicet Bio, Inc.

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $37.2M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

More about ACET

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account